Eric Lefkofsky is a well-known American entrepreneur. He grew up in Michigan and graduated from the University of Michigan in 1991 with honors. Eric later attended the University of Michigan Law School, where he received his Juris Doctor in 1993.
He began is entrepreneurial ventures after he graduated from Law School. Eric and Brad Keywell partnered together to buy Brandon Apparel. In 1999, they worked together to create an Internet company that was called Starbelly. This site specialized in many promotional products. Starbelly experienced rapid ‘pre-bubble’ Internet growth, as a result it was later sold to the Halo Industries in January of 2000.
In 2001, Eric worked to help co-found InnerWorkings. This company provided print procurement services for many mid-sized companies. As time when on, the company was able to achieve solid year-to-year growth. In August 2006, InnerWorkings had a successful initial public offering in the stock market.
He later went one to partner with Brad Keywell to create a freight logistic company called Echo Global Logistics. This project attracted financing from New Enterprise Associates, which is one of the largest technology investors in the country. As time went on, Eric has cofounded many other well-known companies, such as Lightbank, Groupon, Uptake Technologies, and Mediaocean. However, his best known entrepreneurial venture was Tempus.
In 2016, Eric Lefkofsky co-founded Tempus, and currently works as the CEO. Tempus is a technological company that has created an operating system to battle cancer. It does this by allowing physicians to be able to deliver personalized cancer care by using an interactive analytical and machine learning platform. Tempus is also able to provide genomic sequencing services, molecular analysis, and therapeutic data.
-Genomic Sequencing works to give doctors a better understanding of every patient’s tumor. It makes patient care more personalized, which results in better results.
-The analytic platform makes it easy for doctors to gain a well-rounded understanding of their patient’s cancer. It analyzes data in context of patients that have similar molecular profiles. This gives doctors the opportunity to offer more a personalized treatment plan and more active clinical trials.
-By using independent and collaborative biological testing, Tempus is able to work with doctors and researchers to create cell-culture and automation technology.
This technology allows physicians to make real-time and data-driven decisions. They strive to have each patient benefit from the treatment of others by providing all physicians with tools that are able to learn as we gather more information.
Learn more about Eric Lefkofsky by visiting www.lefkofsky.com